Normally, NOTCH1 in VICs helps to prevent the expression of BMP2 and RUNX2, which are osteogenic factors, meaning that some patients may be genetically susceptible to developing CAVD. This evidence concerns the gene BMP2 and congenital bilateral aplasia of vas deferens from CFTR mutation.